A recent study conducted by global industry analysts Frost & Sullivan clarifying the state and dynamics of genomic technology adoption and utilization in the U.S. has concluded that microarray technology—the cornerstone of two decades of discovery—will remain relevant to the advancement of biomedical research and translational medicine in the future. Moreover, while excitement for next-generation sequencing (NGS) remains justifiably high, genomics research remains sustained by mainstay platforms, like those manufactured by Affymetrix, Inc. (NASDAQ:AFFX) 1. The study focused on awareness, adoption plans, usage, and preferences for 15 technologies and 30 applications, and surveyed more than 300 life science researchers from six end-user segments: academic institutions/medical centers, pharmaceuticals, biotechnology companies, and labs in federal or state government, hospitals, and clinics. “In reality, biomedical researchers within academia, biotechnology and pharmaceutical companies, and government laboratories recognize the limitations of next-generation sequencing,” said Jonathon Witonsky, Industry Manager for Frost & Sullivan’s Life Science Research Tools and In vitro Diagnostics Industry Research Group. “These researchers continue to regard microarrays as extremely relevant to their primary applications.” Furthermore, Affymetrix ranked highest among these researchers’ preference for genomic technology suppliers, with 59 percent of current and future microarray users selecting Affymetrix as their preferred microarray provider by a significantly wide margin compared to the nearest competitors Illumina and Agilent, which received 11 percent and 9 percent, respectively. In its analysis of the study, Frost & Sullivan noted that even as researchers are showered by claims that NGS is the appropriate solution for all genomics applications, they realize that the microarray is an invaluable tool for a significant portion of their projects 1. For example, 60 percent of 95 researchers conducting whole-genome expression profiling, and nearly 40 percent of 61 conducting whole-genome transcriptome analysis and whole-genome copy number variation/loss of heterozygosity studies indicated that microarrays are their technology of choice and preferred format; no other single technology had greater than Affymetrix’ percentage. Moreover, nearly 50 percent of the 59 who selected translational research as their future area selected microarrays as the “best fit” technology, behind only qPCR/RT-PCR and high-throughput screening analysis. Frost & Sullivan concluded that Affymetrix microarrays have a thriving market in key research areas, such as expression profiling of focused whole-genome small RNAs and microRNAs, genotyping of candidate genes, and whole-genome studies, because of high awareness and adoption rates of microarray technology. Of the 266 respondents who reported being aware of the technology, nearly 60 percent have already adopted microarrays and approximately 30 percent say they will likely adopt in the next two years.
To learn more about the Frost & Sullivan recognition award and Affymetrix click here.About Affymetrix Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More than 2,100 systems have been shipped around the world and more than 23,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2010, and other SEC reports for subsequent quarterly periods. NOTE: Affymetrix, and the Affymetrix logo, are trademarks or registered trademarks of Affymetrix, Inc. 1 Frost & Sullivan. Best Practices Research White Paper. Product Leadership, Life Science Research Tools North America, 2011.